Companies

Bought Seagen for $43B to become an ADC leader; also makes Ibrance, Lorbrena, Braftovi, and the first PROTAC.

Pioneer of checkpoint inhibitors (Opdivo, Yervoy), now betting on the first successful bispecific ADC and alpha radiopharmaceuticals.

Creator of Herceptin, Avastin, and Rituxan, and owner of Foundation Medicine; the company that defined antibody oncology.

The company that made radioligand therapy a business, with Pluvicto and Lutathera, and the maker of Kisqali and Gleevec.

AstraZeneca is the most ADC-committed large pharma, co-owner of Enhertu and Datroway, with deep targeted-therapy and radiopharma bets.

Merck & Co. (MSD) makes Keytruda, the world's best-selling cancer drug, and is now building the next act around TROP2 ADCs and personalised vaccines.

Johnson & Johnson leads in multiple myeloma (Darzalex, Carvykti, Tecvayli, Talvey) and in bispecific antibodies for lung cancer (Rybrevant).

Takeda co-owns Adcetris outside the US and is developing STING-agonist conjugates and CAR-NK cells.

Sanofi makes Sarclisa (isatuximab), now in a subcutaneous form approved in July 2026.

AbbVie owns Venclexta and Elahere, and bought Capstan, the leading in vivo CAR-T company.

Amgen invented the BiTE T-cell engager format and the first KRAS inhibitor.

Bayer owns Xofigo, the only approved alpha emitter, and is developing next-generation actinium PSMA agents.

Eli Lilly makes Verzenio and Retevmo, as well as the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib.

Daiichi Sankyo is the Japanese company whose DXd payload technology created the best ADC platform in the industry.

Gilead owns Trodelvy (via the $21B Immunomedics deal) and the Kite CAR-T franchise.

Ipsen is the French pharma behind Onivyde (liposomal irinotecan) and the NALIRIFOX regimen, and marketer of tovorafenib in Europe.

Astellas co-owns Padcev and makes Vyloy, the first Claudin 18.2 drug.

BeOne Medicines makes Brukinsa, the leading BTK inhibitor, and tislelizumab, and is the Asia partner for zanidatamab.

Genmab is the Danish antibody engineering company behind the DuoBody platform, Tivdak, Epkinly, and (via ProfoundBio) rinatabart sesutecan.

Incyte makes pemigatinib, the first targeted drug approved for bile duct cancer (2020), and the JAK inhibitor ruxolitinib.

Jazz Pharmaceuticals commercialises zanidatamab (Ziihera) outside Asia.

Chinese biotech whose ivonescimab beat Keytruda head-to-head, and developer of the Nectin-4×TROP2 ADC.

GSK makes Jemperli, Zejula, and the twice-approved myeloma ADC Blenrep.

Regeneron makes Libtayo and has a large portfolio of CD3 bispecifics (odronextamab, linvoseltamab).

Servier is the private French pharma that brought vorasidenib, the first low-grade glioma drug, to market.

Private German pharma whose zongertinib became the first oral HER2 inhibitor for lung cancer.

Revolution Medicines is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer.

Private US company that took over Tecelra and lete-cel from Adaptimmune in 2025 and markets eflornithine (Iwilfin) for neuroblastoma.

First company with FDA-cleared AI pathology tests that predict treatment benefit (prostate 2025, breast 2026).

Blue Earth Diagnostics makes Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.

Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.

Kinase-switch-control company behind ripretinib for GIST and vimseltinib for tenosynovial giant cell tumour; bought by Ono Pharmaceutical in 2024.

Japanese pharma that makes lenvatinib (Lenvima), a first-line option in liver cancer and a partner of pembrolizumab in several tumours.

Ferring is the private Swiss pharma that brought the first bladder cancer gene therapy, Adstiladrin, to market.

Inventor of the ImmTAC soluble TCR bispecific; tebentafusp was the first to improve survival in a solid tumour.

Jiangsu Hengrui is China's largest oncology pharma, maker of pyrotinib and the HER2 ADC trastuzumab rezetecan, and one of the biggest out-licensers of Chinese assets.

Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026.

Menarini is the private Italian pharma that commercialises the first oral SERD, elacestrant.

Dutch bispecific antibody company behind zenocutuzumab and petosemtamab; acquired by Genmab in 2025.

Designer of cleaner kinase inhibitors; zidesamtinib (ROS1) approved July 2026, neladalkib (ALK) next.

SystImmune developed iza-bren, the first bispecific ADC to win a phase 3 trial.

Adaptimmune developed Tecelra, the first TCR-T for a solid tumour, and sold the US rights to US WorldMeds in 2025 amid financial distress.

ADC Therapeutics developed Zynlonta and the PBD-payload ADC platform.

PROTAC pioneer whose vepdegestrant became the first approved targeted protein degrader in 2026.

UCL spin-out whose fast-off-rate CD19 CAR-T, obe-cel, was approved for adult ALL in 2024 with lower neurotoxicity than earlier products.

AVEO Oncology developed tivozanib and was acquired by LG Chem in 2023.

Inventor of bicyclic peptide drug conjugates; its lead Nectin-4 conjugate was deprioritised in 2026 after regulatory feedback.

From COVID vaccine to a broad oncology pipeline: personalised vaccines, ADCs from China, and a PD-L1×VEGF bispecific sold to BMS for $11B.

CARsgen Therapeutics developed satri-cel, the first CAR-T approved for a solid tumour (gastric cancer, China).

Celcuity developed gedatolisib, approved in July 2026 for hormone-positive breast cancer.

CG Oncology developed cretostimogene, the oncolytic virus for early bladder cancer, and is filing for approval in 2026.

Corcept is a cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026.

Paediatric-first oncology company whose tovorafenib became the first targeted therapy for childhood low-grade glioma.

Elevar Therapeutics developed rivoceranib, whose combination with camrelizumab has beaten sorafenib in liver cancer but has been refused by the FDA three times on manufacturing grounds.

Small biotech developing lymph-node-targeted KRAS vaccines for pancreatic and colorectal cancer.

ESSA Pharma developed masofaniten, an AR N-terminal-domain inhibitor whose phase 2 was stopped for futility in 2024-25.

Exact Sciences makes Cologuard and Oncotype DX and is launching Cancerguard MCED and Oncodetect MRD; it is being acquired by Abbott for $21B.

Exelixis makes cabozantinib (Cabometyx), used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.

Maker of the FDA-approved FoundationOne CDx genomic test used across dozens of drug labels.

Freenome makes SimpleScreen CRC, the second FDA-approved blood test for colorectal cancer screening (July 2026), commercialised by Abbott.

Alpha-emitter company acquired by AstraZeneca ($2.4B, 2024); FPI-2265 (225Ac-PSMA-I&T) in phase 3.

GE HealthCare is a major maker of PET/CT, MRI, and CT scanners, and of PET tracers via Pharmaceutical Diagnostics.

Generative-AI protein design company (Flagship) that went public in 2026 and is testing an antibody that neutralises leaked ADC payload to reduce side effects.

GRAIL developed Galleri, the multi-cancer blood test awaiting an FDA decision after a September 2026 advisory committee.

Liquid biopsy leader: Guardant360 for genotyping, Reveal for MRD, Shield for screening.

ImmunityBio makes Anktiva, the IL-15 superagonist approved with BCG for bladder cancer in 2024.

Iovance makes Amtagvi, the first approved TIL therapy.

ITM is the largest non-carrier-added lutetium-177 supplier and the developer of ITM-11 (177Lu-edotreotide).

Jiangsu Hengrui is China's largest innovative pharma, maker of the PD-1 antibody camrelizumab and a broad ADC pipeline.

Karyopharm makes selinexor, the first nuclear export inhibitor, approved in myeloma; its endometrial cancer bet failed in 2026.

Chinese biotech whose joint venture KYM Biosciences created the Claudin 18.2 ADC CMG901, licensed to AstraZeneca in 2023.

Kura Oncology developed ziftomenib, the second menin inhibitor approved for leukaemia (November 2025), in partnership with Kyowa Kirin.

Legend Biotech is the Chinese-origin developer of Carvykti, the most effective myeloma CAR-T, with J&J.

MacroGenics is the antibody engineering company behind margetuximab and several bispecific and ADC programmes.

Moderna is the mRNA company whose personalised cancer vaccine intismeran won the first phase 3 in the class (August 2026).

Natera makes Signatera, the dominant tumour-informed MRD test.

Northwest Biotherapeutics developed the DCVax-L dendritic cell vaccine for glioblastoma and is seeking UK approval on contested phase 3 data.

Novocure makes Optune tumour treating fields, approved in glioblastoma, lung, mesothelioma, and (2026) pancreatic cancer.

Orano Med is the leading lead-212 producer and the developer of 212Pb-DOTAMTATE (AlphaMedix).

Spanish company that turns marine natural products into cancer drugs, including lurbinectedin and trabectedin.

Puma Biotechnology developed neratinib (Nerlynx), the extended-adjuvant HER2 pill.

Quanta Therapeutics develops oral multi-KRAS inhibitors biased to G12D (QTX3034) and G12V (QTX3544), with responses in pancreatic, colorectal, and endometrial cancer.

RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation.

RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.

RemeGen developed disitamab vedotin, China's first domestic ADC.

Oncolytic virus company whose RP1 (Tudriqev) was approved in August 2026 after an initial FDA rejection.

Commercialises olutasidenib (Rezlidhia), an IDH1 inhibitor for relapsed AML, alongside fostamatinib.

Chinese biosimilar and biologics company whose PD-1 antibody serplulimab is approved in China and Europe for small-cell lung cancer.

Chinese ADC developer whose TROP2 ADC sac-TMT was licensed to Merck in one of the largest China-out deals.

SpringWorks developed nirogacestat, the first approved treatment for desmoid tumours, and mirdametinib for NF1 plexiform neurofibromas; Merck KGaA acquired it in 2025.

Sumitomo Pharma makes Orgovyx (relugolix), the first oral GnRH antagonist for prostate cancer.

Summit Therapeutics holds Western rights to ivonescimab and is running the global HARMONi trials.

Cell-free protein synthesis ADC company that refocused on exatecan and dual-payload ADCs, deprioritising its folate-receptor ADC luveltamab.

Syndax developed the first menin inhibitor, revumenib.

Taiho Oncology makes Inqovi, the oral decitabine-cedazuridine that in May 2026 became the first all-oral hypomethylating backbone for venetoclax in AML.

Japanese oncology company behind futibatinib (Lytgobi) for bile duct cancer and the chemotherapy Lonsurf; acquired the ADC linker company Araris in 2025.

Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline.

Chinese biotech running the first phase 3 of a next-generation FGFR inhibitor, tinengotinib, for bile duct cancer that has stopped responding to first-generation FGFR drugs.

Veracyte makes the Decipher genomic classifier, the most-used gene-expression test in localised prostate cancer.

RAS/MAPK-pathway company whose avutometinib + defactinib combination became the first approved treatment for KRAS-mutant low-grade serous ovarian cancer (May 2025).

MSK spin-out that commercialises naxitamab, the humanised anti-GD2 antibody for relapsed neuroblastoma, and develops pretargeted radioimmunotherapy.

Zymeworks invented zanidatamab and a hydrophilic TOP1 ADC platform (ZW191 FRα, ZW251 GPC3).

Leader in single-cell and spatial biology tools (Chromium, Visium, Xenium) used to dissect tumours.

Hungarian maker of Pannoramic slide scanners and the SlideViewer software, widely used in research and European clinical labs.

Abzena is a bioconjugation and biologics CDMO with the ThioBridge site-specific linker technology.

Adaptive Biotechnologies makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in ALL, myeloma, and CLL.

Agilent makes the Dako PD-L1 IHC 22C3 and 28-8 companion diagnostics and the Omnis staining platform.

Radiology AI company with the first FDA-cleared foundation-model triage platform (CARE, January 2026); oncology-relevant for incidental findings and workflow.

Aignostics is the Berlin pathology AI company that built the Atlas foundation model with Mayo Clinic.

Spatial proteomics (PhenoCycler, PhenoImager) used to map immune cells in tumours; agreed to be acquired by Quanterix (2025).

Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3.

Leading GMP plasmid DNA and mRNA raw-material supplier, acquired by Danaher for $9.6B in 2021.

Allogeneic CAR-T leader: cema-cel (CD19) as MRD-guided first-line consolidation in lymphoma, and ALLO-316 (CD70) with responses in kidney cancer.

Swiss linker-technology company (AraLinQ) acquired by Taiho for up to $1.14B; first clinical ADC ARC-02 (CD79b) dosed in June 2026.

Programmable CAR-T company using logic gates so cells fire only when two tumour proteins are present; AB-2100 (PSMA + CA9) is in phase 1/2 for kidney cancer.

Avenzo in-licenses Chinese assets, including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor.

German medical-device company supplying Celsite ports, Easypump elastomeric pumps, infusion systems, and cytotoxic-safe consumables.

Infusion pumps (Spectrum, Novum), elastomeric ambulatory pumps (Infusor), IV fluids and generic injectables.

Medical technology company supplying closed-system transfer devices (PhaSeal), infusion systems, flow cytometers, and single-cell tools.

Maker of CryoStor freeze media used in most approved cell therapies, plus evo cold-chain shippers.

French startup behind H-optimus-0, an open 1.1-billion-parameter pathology foundation model.

Boehringer Ingelheim BioXcellence is the contract-manufacturing arm of Boehringer Ingelheim, one of the largest antibody producers by volume.

Medical device giant whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer.

BostonGene integrates genomic, transcriptomic, and immune microenvironment analysis into a 'Tumor Portrait'.

Surgical navigation and radiosurgery planning software (Elements), used in neurosurgery and stereotactic radiotherapy.

Scientific-instrument group that acquired NanoString (GeoMx, CosMx) out of bankruptcy in 2024 to form Bruker Spatial Biology.

Bulsara Bioworks is a 2025 start-up focused on precise p53-pathway activation for solid tumours.

Degrader company whose IKZF1/3 molecular glue cemsidomide showed a 53% response rate in heavily pretreated myeloma and entered phase 2 in 2026.

Imaging core lab and RTSM provider (formerly Parexel Informatics), a leading vendor of blinded central review in oncology trials.

Nonprofit that helps advanced-cancer patients navigate precision-oncology options and trials, free of charge.

Canon Medical is the Japanese imaging vendor (formerly Toshiba Medical) with CT, MRI, ultrasound, and the Cartesion Prime PET/CT.

Nuclear pharmacy network (>130 sites) that compounds and delivers SPECT and PET doses, and a distributor of oncology drugs to community practices.

CRISPR-edited allogeneic CAR-T company whose vispa-cel (CB-010) matched autologous CAR-T efficacy in lymphoma in 2025 data.

Whole-exome and whole-transcriptome tumour profiling at scale, with a large real-world database.

Major fill-finish and gene-therapy CDMO, acquired by Novo Holdings in 2024 with three sites transferred to Novo Nordisk.

Cellares builds the Cell Shuttle, a fully automated 'smart factory' for cell therapies, with BMS and Kite as partners.

Biotech that ran one of the early GPNMB ADCs in triple-negative breast cancer, which failed, and has since pivoted to mast-cell (KIT) antibodies for allergic disease.

Makes Chai-1 and Chai-2, open-weight structure models used for antibody and binder design.

Oncology CRO with the largest bank of patient-derived xenograft models (TumorGraft), now adding 3D organoid screening and radiopharmaceutical services.

Funds and builds the Human Cell Atlas infrastructure and the CZI virtual cell models (TranscriptFormer), plus one of the largest nonprofit GPU clusters for biology.

Preclinical CRO for safety and discovery studies, with viral vector and cell-therapy manufacturing services.

Circle Pharma is developing CID-078, the first oral cyclin A/B RxL inhibitor, aimed at cancers with a broken G1/S checkpoint such as small-cell lung and triple-negative breast cancer.

Non-profit generic drug maker formed by hospital systems to secure supply of essential injectables, including oncology drugs.

Clario is the endpoint technology company (Bioclinica and ERT merger) for imaging, eCOA, and cardiac data in trials.

Copper theranostics company: Cu-64 SAR-bisPSMA for PET (phase 3 AMPLIFY/CLARIFY) and Cu-67 SAR-bisPSMA for therapy.

Italian maker of hot cells, isolators, and dose calibrators for radiopharmacies, part of ATS Corporation.

Oncology real-world data and AI company (ex-CancerLinQ data partner), supplying pharma and FDA-facing studies.

Curated oncology real-world data with clinically abstracted endpoints, used in FDA-recognised RWE studies.

Cradle is a protein-engineering AI platform used by pharma to optimise antibodies and enzymes.

Cryoport is a specialist cryogenic logistics provider supporting most commercial CAR-T products and hundreds of cell-therapy trials.

Israeli company whose cResponse test keeps a patient's tumour fragment alive, with its vessels and immune cells, to test which treatments it responds to.

Danaher's bioprocessing arm (formerly GE Healthcare Life Sciences), supplying the Sefia cell-therapy platform, chromatography, and single-use systems.

Privacy-preserving record linkage (tokenisation) that lets real-world datasets be joined without exposing identities.

Debiopharm is the private Swiss developer of the WEE1 inhibitor zedoresertib (Debio 0123) and of dual-payload ADC research.

Fragmentomics company whose FirstLook Lung blood test aims to raise lung-cancer screening uptake; first randomised clinical-utility data in 2026.

Discovery Life Sciences is a large commercial biospecimen and biomarker services provider (tissue, blood, cells) for pharma and diagnostics.

Secure genomics cloud platform behind the UK Biobank Research Analysis Platform and Genomics England's research environment.

Chinese ADC platform company behind BioNTech's trastuzumab pamirtecan (BNT323/DB-1303) and AI-nominated targets.

German isotope and radiopharmaceutical services company supplying Lu-177, Ga-68 generators, Ac-225 development, and contract manufacturing.

Elekta is the Swedish radiotherapy company behind Unity, the leading MR-linac, and Gamma Knife.

AVITI benchtop sequencer with avidity chemistry, competing on accuracy and cost with mid-throughput Illumina systems.

Spatial multi-omics service that images DNA, RNA, and protein from the same tissue slide to predict therapeutic response.

Epic Systems is the dominant US hospital EHR; its Beacon oncology module handles chemotherapy ordering and Cosmos aggregates de-identified records for research.

Spun out of Meta's protein team; makes the ESM3 protein language model that generated a new fluorescent protein.

Fate Therapeutics builds iPSC-derived off-the-shelf CAR-T and CAR-NK cells (FT819, FT522) for cancer and autoimmune disease.

Y Combinator Spring 2026 start-up building a programmable DNA-targeting drug: a molecule that recognises a cancer-specific DNA sequence inside a cell and triggers a kill switch only there.

Oncology EHR (OncoEMR) and the largest curated real-world oncology database, acquired by Roche for $1.9B in 2018.

Florida Cancer Specialists is one of the largest independent oncology practices in the US and a leading phase 1 enroller through its Drug Development Unit.

Stanford spin-out whose PhasED-Seq ctDNA technology detects residual lymphoma more accurately than PET/CT; clinical launch of CLARITY in 2026.

Fortrea is the CRO spun out of Labcorp in 2023.

Fresenius Kabi supplies apheresis devices (Amicus, LOVO), generic oncology injectables, biosimilars, and infusion products.

Chemoproteomics company with FMC-376, a KRAS G12C inhibitor that hits both the ON and OFF states of the protein, in phase 1/2.

FUJIFILM Diosynth is a large biologics CDMO building major antibody capacity in Denmark and North Carolina.

Galapagos is a biotech pursuing decentralised, seven-day vein-to-vein CAR-T manufacturing at hospital sites; it restructured its cell-therapy business in 2025.

Genesis Molecular AI does small-molecule discovery on its GEMS platform, which combines physics and deep learning, with oncology programmes in the clinic pipeline.

Alphabet's health efforts: mammography and pathology AI research, Med-PaLM/MedGemma medical models, DeepMind's AlphaFold, and Isomorphic Labs drug design.

Google DeepMind built AlphaFold, AlphaMissense, AlphaGenome and Med-Gemini, the reference models for structure, variants, and medical multimodal reasoning.

Neoantigen-vaccine pioneer (GRANITE, SLATE) that ran out of money and filed for bankruptcy in October 2024; a cautionary tale for the personalised-vaccine field.

Hamamatsu is the photonics company behind the NanoZoomer slide scanners and the photodetectors inside most PET scanners.

Flagship-founded blood-test company launching RESOLVE, a multi-cancer detection test for people with symptoms who are waiting for a diagnosis.

HistAI released the open Hibou pathology foundation models.

Inventor of histotripsy, non-invasive tumour destruction with focused ultrasound bubbles; acquired for $2.25B in 2025.

The Clevers-lab spin-out that licenses patient-derived organoid technology and maintains a living biobank.

AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2/4 inhibitor.

IBA is the largest supplier of proton therapy equipment.

ICON is an Irish CRO (including PRA Health Sciences) with a large oncology franchise and an imaging core lab.

Illumina is the dominant DNA sequencing platform underneath nearly every genomic test in oncology.

TCR-T company whose PRAME-directed anzu-cel (IMA203) is in the phase 3 SUPRAME trial in melanoma, with a launch targeted for 2027.

HALO image-analysis and HALO Link management software, widely used in pharma and academic pathology.

Indivumed is a German biobank with standardised, rapidly processed tumour samples and a multi-omics database (IndivuType).

MR-guided focused ultrasound company, with oncology use in blood-brain-barrier opening for brain tumours.

Generative-AI drug discovery company, listed in Hong Kong in December 2025, with a pan-KRAS candidate and a pan-TEAD inhibitor in the clinic.

Penn spin-out that dosed the first patient ever with a durable in vivo CAR gene therapy (INT2104, CD20) in the INVISE trial.

Intuitive Surgical makes the da Vinci robot, used in most robotic cancer surgeries worldwide.

IQVIA is the largest CRO and health-data company, running a large share of global oncology trials and selling prescription and claims data.

Alphabet's AlphaFold-derived drug design company; its first AI-designed oncology candidate was cleared for human trials in January 2026 after a $2.1B raise.

Jubilant Radiopharma is a radiopharmacy network and the manufacturer of I-131 MIBG (AdreView), Ruby-Fill, and PET tracers.

Dutch-Swiss company releasing open pathology foundation models (Midnight) and evaluation tooling (eva).

Digital patient-monitoring platform for cancer care, acquired by Elekta in 2020.

Claims-based 'Healthcare Map' of 330 million US patients used for market and outcomes analytics in oncology.

Oral degrader company, mostly immunology, whose CDK2 molecular-glue degrader was optioned by Gilead in 2026 for CCNE1-driven cancers.

Labcorp is one of the two US national reference labs, running oncology IHC, FISH, and NGS at scale and central labs for trials.

Founded by an AlphaFold co-developer to make protein design programmable; released Latent-X in 2025.

Pathology workflow leader: Aperio slide scanners, BOND IHC stainers, and companion-diagnostic assays.

Lila Sciences is Flagship Pioneering's 'scientific superintelligence' company, combining AI with autonomous labs, with life science as a first domain.

Limbus AI provides AI auto-contouring for radiotherapy, FDA-cleared and used across hundreds of centres.

Lonza is the largest contract manufacturer for biologics, ADCs, and cell therapies, and owns the Synaffix ADC linker technology and the Cocoon cell-manufacturing platform.

Korean AI company spanning mammography reading (INSIGHT MMG), breast-density risk (Volpara), and AI pathology for immunotherapy biomarkers.

McKesson runs the largest US community oncology network (about 3,000 providers) and distributes drugs, and co-owns the Sarah Cannon Research Institute.

Medable is a decentralised clinical trial platform (eConsent, eCOA, telehealth).

Rave, the most used electronic data capture system in clinical trials, plus synthetic control arm services.

MediLink developed the TMALIN ADC linker platform, licensed to Zai Lab, BioNTech, and Roche.

Medpace is a mid-size full-service CRO popular with biotechs, including for oncology programmes.

ADC platform company betting on B7-H4: emiltatug ledadotin (Emi-Le) has Breakthrough designation in adenoid cystic carcinoma and activity in TNBC after TOP1 ADCs.

Mevion makes compact single-room proton therapy systems.

Chinese sequencing-instrument maker (DNBSEQ), Illumina's main rival by volume, restricted in the US by the BIOSECURE Act.

Cloud and AI provider behind pathology foundation models (Prov-GigaPath with Providence, Virchow hosting with Paige) and Nuance clinical AI.

Microsoft co-developed Prov-GigaPath and BiomedCLIP and is the compute partner for Paige's Virchow2.

Miltenyi Biotec makes the CliniMACS Prodigy, the closed cell-processing device many academic CAR-T programmes are built on.

Contouring, image fusion, and dosimetry software (MIM Maestro, SurePlan) for radiotherapy and radioligand therapy, acquired by GE HealthCare in 2024.

Molecular-glue degrader company with a GSPT1 degrader in phase 2 for AR-mutant prostate cancer and a CCNE1-directed glue in preclinical development.

MORE Health is a cross-border telemedicine company delivering expert second opinions from leading specialists for serious illness including cancer.

German antibody company that acquired Constellation's BET inhibitor pelabresib and was itself bought by Novartis in 2024.

MVision AI is a Finnish auto-contouring company with guideline-based organ and target segmentation.

Cancer navigation consultancy that helps patients find, understand, and enrol in biomarker-matched clinical trials.

Cancer-focused reference lab for IHC, FISH, flow cytometry, and NGS, serving community oncology and pharma.

CAR-NK company that shelved its oncology programmes after falling response rates and pivoted to autoimmune disease.

NorthStar is a non-reactor producer of Mo-99 in the US and an emerging supplier of non-carrier-added Lu-177 and Ac-225 made with electron accelerators.

Nouscom is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens to intercept cancer in Lynch syndrome carriers.

Nurix Therapeutics is developing bexobrutideg, a brain-penetrant BTK degrader in pivotal trials for CLL, co-developed with Roche from June 2026.

Supplies the GPUs and the BioNeMo framework most biological foundation models are trained on, and co-developed Evo 2 with Arc.

Omnicell is a pharmacy automation company whose IV compounding systems prepare chemotherapy safely.

Physician-led community oncology network backed by TPG and Cencora (AmerisourceBergen), competing with US Oncology.

Oracle owns the Cerner EHR (PowerChart Oncology) and the Oracle Clinical One trial platform.

Circular-RNA in vivo CAR company bought by Eli Lilly for about $2.4B in February 2026.

French AI biotech using federated learning across hospitals; first CE-marked AI for MSI prediction from H&E.

Pure-play viral vector CDMO that made lentiviral vector for Kymriah and manufactured the AstraZeneca COVID vaccine.

Portable and high-throughput nanopore sequencing, used for rapid intraoperative brain-tumour classification and structural variant detection.

Long-read HiFi sequencing (Revio, Vega) for structural variants, phasing, and methylation.

MSK spin-out with the first FDA-cleared AI pathology product and the Virchow foundation model.

Parexel is a global CRO with strong regulatory consulting (many ex-FDA staff) and oncology trial operations.

PathAI runs the AISight AI pathology platform and quantifies biomarkers for pharma trials.

AI clinical-trial matcher for cancer patients: upload records or connect a health system, get explained matches updated daily from ClinicalTrials.gov.

Maker of the ultra-sensitive NeXT Personal MRD test, being acquired by Tempus AI for about $1.5B (announced July 2026).

Lead-212 alpha-therapy company whose SSTR2 agent [212Pb]VMT-α-NET reported a 43% response rate in neuroendocrine tumours and is heading for phase 3.

PETNET Solutions is the largest network of PET radiopharmacies in the US, producing FDG and PSMA tracers daily.

Imaging and health-informatics company: MRI, CT, and the IntelliSite digital pathology system that won the first FDA clearance for primary diagnosis.

Piramal Pharma Solutions is a CDMO with ADC conjugation in Grangemouth, Scotland, and high-potency API sites in the US and India.

Profluent uses protein language models to design new gene editors (OpenCRISPR-1) and antibodies.

Proscia makes the Concentriq digital pathology platform for labs and pharma, with an AI marketplace.

QIAGEN is a sample-preparation and molecular-diagnostics company selling nucleic-acid extraction kits, therascreen companion diagnostics, and QCI Interpret software.

Quest Diagnostics is a national reference laboratory with oncology pathology and molecular testing, including Haystack Oncology MRD (acquired 2023).

RaySearch makes the vendor-neutral RayStation treatment planning system, strong in proton and adaptive planning, with machine-learning planning tools.

Recursion is an AI-first biotech (merged with Exscientia in 2024) with a clinical oncology pipeline that includes an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis.

RefleXion Medical makes the first PET-guided radiotherapy system, which uses the tumour's own emissions to steer the beam.

Sakura Finetek is a histology automation leader (Tissue-Tek processors, embedders, stainers, and the Genie IHC platform).

Samsung Biologics is the world's largest biologics CDMO by capacity, and opened a dedicated ADC conjugation facility in 2025.

Sana Biotechnology is a hypoimmune cell-therapy company that suspended its oncology allogeneic CAR-T (SC262) in late 2025 and pivoted to type 1 diabetes and in vivo CAR-T (SG293).

Large community-based research network (HCA Healthcare and McKesson joint venture) that runs many early-phase oncology trials.

Pioneer of the 'metasite' decentralised trial model, acquired by eMed in 2024.

Enterprise imaging and digital pathology software used by many European and UK health systems for fully digital pathology.

Runs the PARIS test: a patient's tumour grown as organoids and screened against 240+ drugs to find options sequencing cannot see.

Serova is an early-stage company building a personalised cancer vaccine platform that redesigns the vaccine as the tumour evolves.

SHINE Technologies is a fusion-based isotope company that produces non-carrier-added Lu-177 (Ilumira) and is building the Chrysalis Mo-99 plant.

Siemens Healthineers makes the Biograph Vision Quadra total-body PET and photon-counting CT, and owns Varian.

Sirtex makes SIR-Spheres, yttrium-90 resin microspheres used for radioembolisation of liver tumours.

SOFIE Biosciences is a US radiopharmacy network running two phase 3 trials of the FAP PET tracer [18F]FAPI-74 in pancreatic and gastro-oesophageal cancer.

Cloud platform (SOPHiA DDM) that hospitals use to analyse and interpret NGS oncology panels.

Proteomics and mass-cytometry company that merged with SomaLogic (SomaScan aptamer proteomics) in 2024.

Streck makes the Cell-Free DNA BCT blood tube that made shippable liquid biopsy practical.

Radiotherapy quality-assurance instruments and software (SunCHECK, ArcCHECK) that verify machines deliver the planned dose.

Licensor of the GlycoConnect site-specific ADC conjugation platform, now part of Lonza and used by dozens of ADC developers.

Genomic testing plus one of the largest multimodal clinical datasets, used for AI models and trial matching.

Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility to raise supply 20-fold.

Maker of the Spectra Optia apheresis system used to collect cells for most CAR-T products, and of the Quantum cell-expansion system.

TheraPanacea is a Paris AI company whose ART-Plan does auto-contouring and synthetic CT in radiotherapy.

Thermo Fisher is the largest life-science tools and services company, spanning Ion Torrent sequencing (Oncomine), viral vector and fill-finish manufacturing (Patheon), and the PPD clinical research organisation.

Cell-free synthetic DNA (doggybone dbDNA) as an alternative to plasmids for vectors and mRNA templates.

Belgian maker of radiopharmaceutical synthesis modules (AllinOne, miniAiO) and dose dispensers used in PET and therapy radiopharmacies.

Federated real-world data network across health systems, used for trial feasibility and observational studies.

TCR discovery company that cut 75% of staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours (PRAME, MAGE-A4).

German ADC company whose NaPi2b ADC TUB-040 posted a 59% response rate in platinum-resistant ovarian cancer; Gilead agreed to buy it for up to $5B.

Open-wafer sequencing (UG 100) claiming a $100 genome, aimed at population-scale and deep ctDNA sequencing.

In vivo CAR-T company using lentiviral vectors (VivoVec); first CD22-directed in vivo CAR-T cleared for US trials in 2026.

Chinese imaging company that built uEXPLORER, the first total-body PET scanner.

Valius is a patient-centred multi-omic profiling service that runs whole genome, bulk and single-cell RNA, spatial transcriptomics, high-plex protein, and ctDNA on one tumour.

Varian is the largest radiotherapy equipment maker and is running the first human FLASH proton trials.

Cloud software for life sciences: Vault CDMS for trials, plus regulatory, quality, and commercial systems.

Genomics cloud and clinical interpretation company formed from Seven Bridges, Pierian, and UgenTec in 2023; operates the NCI Cancer Genomics Cloud.

Produced Tahoe-100M, the largest single-cell drug-perturbation atlas, and trains models on it.

Vizgen sells the MERSCOPE spatial transcriptomics platform, based on MERFISH from Xiaowei Zhuang's lab.

WuXi XDC is the largest dedicated ADC CDMO, spun out of WuXi Biologics and listed in Hong Kong in 2023; it is exposed to US BIOSECURE Act politics.

Launched in 2024 with over $1 billion to build AI-native drug discovery from Baker-lab protein design.

Xencor is an antibody-engineering company (XmAb Fc technology) developing 2+1 T-cell engagers for kidney cancer (ENPP3) and ovarian/germ-cell tumours (CLDN6).

Duke spin-out whose MicroOrganoSphere droplets grow a patient's tumour and screen drugs within two weeks.